Advances in immunotherapy for non-small cell lung cancer
10.3969/j.issn.1000-8179.2018.04.985
- VernacularTitle:非小细胞肺癌免疫治疗进展
- Author:
Congcong SHANG
1
Author Information
1. 中国医学科学院北京协和医学院
- Keywords:
non-small-cell lung cancer;
immune checkpoints;
combination therapies;
immune resistance
- From:
Chinese Journal of Clinical Oncology
2018;45(4):205-208
- CountryChina
- Language:Chinese
-
Abstract:
The theory of tumor immunity has gone through more than a century of exploration and shown remarkable clinical efficacy. Therapy based on targeting immune checkpoints,especially anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibody monotherapy,has made significant progress in the treatment of advanced lung cancer.Consequently,the discovery of new immune checkpoints has be-come an area of interest.Additionally,combined immunotherapy is expected to be the future direction of immunotherapy.However, at this stage,immunotherapy has not yet resulted in widespread benefit.Identifying immune resistance mechanisms will further pro-mote individualized treatment.
